These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 17380597)

  • 21. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
    dos Santos SR; Passadore LF; Takagi EH; Fujii CM; Yoshioka CR; Gilio AE; Martinez MB
    Vaccine; 2013 Dec; 31(51):6150-4. PubMed ID: 23747454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive pneumococcal disease in children: changing serotypes and clinical expression of disease.
    Calbo E; Garau J
    Clin Infect Dis; 2005 Dec; 41(12):1821-2; author reply 1822-3. PubMed ID: 16288412
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines.
    Picazo JJ
    Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():4-6. PubMed ID: 19366362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease.
    Bliss SJ; O'Brien KL; Janoff EN; Cotton MF; Musoke P; Coovadia H; Levine OS
    Lancet Infect Dis; 2008 Jan; 8(1):67-80. PubMed ID: 17974480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?
    Moore MR; Whitney CG
    Clin Infect Dis; 2008 Jan; 46(2):183-5. PubMed ID: 18171248
    [No Abstract]   [Full Text] [Related]  

  • 27. Promises and challenges of pneumococcal conjugate vaccines for the developing world.
    Grijalva CG; Edwards KM
    Clin Infect Dis; 2006 Sep; 43(6):680-2. PubMed ID: 16912938
    [No Abstract]   [Full Text] [Related]  

  • 28. Heptavalent Pneumococcal Conjugate Vaccine: growing knowledge and its implications for Italy.
    Durando P; Sticchi C; Compagnino F; Ansaldi F; Sticchi L; Gasparini R; Castiglia P; Lugarini J; Alberti M; Icardi G
    J Prev Med Hyg; 2008 Mar; 49(1):34-46. PubMed ID: 18792532
    [No Abstract]   [Full Text] [Related]  

  • 29. Emergence of Streptococcus pneumoniae serotype 15A after the introduction of the conjugate vaccine in Victoria.
    Strachan JE; Rowe SL; Dunne EM; Hogg GG
    Med J Aust; 2013 Oct; 199(7):461-3. PubMed ID: 24099202
    [No Abstract]   [Full Text] [Related]  

  • 30. The conjugate vaccine and invasive pneumococcal disease.
    Konradsen HB; Nokleby H
    N Engl J Med; 2003 Aug; 349(7):714-6; author reply 714-6. PubMed ID: 12921091
    [No Abstract]   [Full Text] [Related]  

  • 31. Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
    Tatochenko V; Sidorenko S; Namazova-Baranova L; Mayanskiy N; Kulichenko T; Baranov A; Lobzin Y; Kharit S; Kozlov R; Andreeva I; Muravjev A; Chagaryan A; Koroleva I; Beloshitskiy G; Mironov K; Degtyareva E; Reinert RR
    Expert Rev Vaccines; 2014 Feb; 13(2):257-64. PubMed ID: 24350587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
    Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction of pneumococcal vaccine to standard immunisation programmes in Europe: what are we waiting for?
    Heininger U
    Eur J Pediatr; 2002 Dec; 161 Suppl 2():S125-6. PubMed ID: 12494257
    [No Abstract]   [Full Text] [Related]  

  • 34. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
    Giglio N; Micone P; Gentile A
    Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive pneumococcal disease and the need for the new 13-valent pneumococcal vaccine.
    Bolton M; Barson W
    Pediatr Ann; 2010 Aug; 39(8):497-503. PubMed ID: 20704146
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of the new pneumococcal conjugate vaccine in the USA.
    Baucher H
    Arch Dis Child; 2000 Nov; 83(5):396. PubMed ID: 11040145
    [No Abstract]   [Full Text] [Related]  

  • 37. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report.
    Wkly Epidemiol Rec; 2010 Oct; 85(43):434-6. PubMed ID: 21038716
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
    Miller E; Andrews NJ; Waight PA; Slack MP; George RC
    Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Worldwide progress in introducing pneumococcal conjugate vaccine, 2000-2008.
    Wkly Epidemiol Rec; 2008 Oct; 83(43):388-92. PubMed ID: 18949860
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.